RECRUITING

The Efficacy of Systemic Valacyclovir (Valtrex) on Periodontitis

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The experiment outlined in this proposal is designed to test the hypothesis that herpesvirus suppression by the systemic anti-herpesvirus valacyclovir (Valtrex) can significantly help to arrest the progressive course of severe marginal periodontitis in adult patients. A prospective, randomized, placebo-controlled, double-blind, clinical trial is employed to test this hypothesis.

Official Title

The Efficacy of Systemic Valacyclovir (Valtrex) to Arrest Further Progression of Severe Periodontitis

Quick Facts

Study Start:2023-05-25
Study Completion:2024-03-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05712343

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients must be systemically healthy, Class I dental category.
  2. * Involved teeth must have periodontal disease detectible by periodontal examination.
  3. * Subjects with deep vertical periodontal lesions (\>6 mm) showing no radiographic crestal alveolar lamina dura
  1. * Presence of any disease or medication that alters the immune system or interferes with healing ability Smokers (more than 10 cigarettes per day)
  2. * External or internal tooth resorption
  3. * Tooth perforation from the pulp cavity through the tip of the root exposing the tissue to material in the oral cavity.
  4. * Pregnant or nursing mothers because hormonal factors may influence the condition.
  5. * Allergies or adverse reactions to valacyclovir.
  6. * Patients under the age of 18.
  7. * Patients with renal impairment or reduced renal function.
  8. * Patients requiring hemodialysis or peritoneal dialysis.

Contacts and Locations

Study Contact

Mike Sabeti, DDS
CONTACT
415-476-0822
mike.sabeti@ucsf.edu

Principal Investigator

Mike Sabeti, DDS
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

University of California, San Francisco
San Francisco, California, 94143
United States

Collaborators and Investigators

Sponsor: University of California, San Francisco

  • Mike Sabeti, DDS, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-05-25
Study Completion Date2024-03-01

Study Record Updates

Study Start Date2023-05-25
Study Completion Date2024-03-01

Terms related to this study

Additional Relevant MeSH Terms

  • Severe Periodontitis